StreetInsider.com News Articles

Instil Bio Inc. (TIL) Misses Q2 EPS by 21c

Fri, 14 Aug 2026 05:55:44 -0400

Instil Bio Inc. (NASDAQ: TIL) reported Q2 EPS of ($0.63), $0.21 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Instil Bio Inc. (TIL) click here.

Form 10-Q Instil Bio, Inc. For: Jun 30

Thu, 13 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26922505.html

Form 10-Q Instil Bio, Inc. For: Jun 30

Thu, 13 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260813/26922505.html

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 17:00:00 -0400

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update.

Recent Highlights:

Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.
Cash position of approximately $69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.

Second Quarter 2026 Financial and Operating Results:

As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 17:00:00 -0400

Recent Highlights:

Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.
Cash position of approximately $69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.

Second Quarter 2026 Financial and Operating Results:

As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 17:00:00 -0400

Recent Highlights:

Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.
Cash position of approximately $69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.

Second Quarter 2026 Financial and Operating Results:

As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Thu, 13 Aug 2026 17:00:00 -0400

Recent Highlights:

Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.
Cash position of approximately $69.9 million as of June 30, 2026 expected to fund current operating plan beyond 2027.

Second Quarter 2026 Financial and Operating Results:

As of June 30, 2026, Instil had cash, cash equivalents, restricted cash and marketable securities

Form 8-K Instil Bio, Inc. For: Aug 13

Thu, 13 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260813/26922455.html

Form 8-K Instil Bio, Inc. For: Aug 13

Thu, 13 Aug 2026 16:59:00 -0400

si-local-file:///var/storage/secattach/20260813/26922455.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: McGaughy R Kent Jr

Fri, 12 Jun 2026 14:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26640159.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: McGaughy R Kent Jr

Fri, 12 Jun 2026 14:40:00 -0400

si-local-file:///var/storage/secattach/20260612/26640159.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: Matcham George

Fri, 12 Jun 2026 14:39:00 -0400

si-local-file:///var/storage/secattach/20260612/26640158.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: Matcham George

Fri, 12 Jun 2026 14:39:00 -0400

si-local-file:///var/storage/secattach/20260612/26640158.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: Gibson Neil W

Fri, 12 Jun 2026 14:38:00 -0400

si-local-file:///var/storage/secattach/20260612/26640157.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: Gibson Neil W

Fri, 12 Jun 2026 14:38:00 -0400

si-local-file:///var/storage/secattach/20260612/26640157.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: Binder Gwendolyn

Fri, 12 Jun 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26640151.html

Form 4 Instil Bio, Inc. For: Jun 11 Filed by: Binder Gwendolyn

Fri, 12 Jun 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26640151.html

Form 8-K Instil Bio, Inc. For: Jun 11

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636204.html

Form 8-K Instil Bio, Inc. For: Jun 11

Thu, 11 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260611/26636204.html

Form 8-K Instil Bio, Inc. For: May 15

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500124.html

Form 8-K Instil Bio, Inc. For: May 15

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500124.html

Form 10-Q Instil Bio, Inc. For: Mar 31

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500138.html

Form 10-Q Instil Bio, Inc. For: Mar 31

Fri, 15 May 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260515/26500138.html

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 15 May 2026 07:00:00 -0400

DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and provided a corporate update.

Recent Highlights

Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027

“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Fri, 15 May 2026 07:00:00 -0400

Recent Highlights

Instil is evaluating potential acquisitions and in-licensing that may provide access to promising novel therapeutic candidates
Cash position of approximately $74.7 million as of March 31, 2026 expected to fund current operating plan beyond 2027

“We continue to make progress refining Instil’s strategy and positioning the company for its next phase of growth,” said